Combination Therapy for Treating Breast Cancer Using Antiestrogen, ERA-923, and the Mammalian Target of Rapamycin Inhibitor, Temsirolimus

Endocrine-Related Cancer - United Kingdom
doi 10.1677/erc.1.01170
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Bioscientifica

Related search

Temsirolimus, an Inhibitor of Mammalian Target of Rapamycin

Clinical Cancer Research
Cancer ResearchOncology
2008English

New Targets for Therapy in Breast Cancer: Mammalian Target of Rapamycin (mTOR) Antagonists

Breast Cancer Research
Cancer ResearchOncology
2004English

Targeting the Mammalian Target of Rapamycin (mTOR): A New Approach to Treating Cancer

British Journal of Cancer
Cancer ResearchOncology
2004English

The Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Early Breast Cancer: Results of a Pre-Operative Study

Breast Cancer Research and Treatment
Cancer ResearchOncology
2010English

Metformin Inhibits Mammalian Target of Rapamycin Dependent Translation Initiation in Breast Cancer Cells

Cancer Research
Cancer ResearchOncology
2007English

Correction: An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-Resistant Functions of mTORC1.

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2020English

Mammalian Target of Rapamycin (mTOR) Inhibition: Potential for Antiseizure, Antiepileptogenic, and Epileptostatic Therapy

Current Neurology and Neuroscience Reports
NeuroscienceNeurology
2012English

Ku-0063794 Is a Specific Inhibitor of the Mammalian Target of Rapamycin (mTOR)

Biochemical Journal
BiochemistryCell BiologyMolecular Biology
2009English

Immunohistochemical Analysis of Phosphorylated Mammalian Target of Rapamycin and Its Downstream Signaling Components in Invasive Breast Cancer

Molecular Medicine Reports
OncologyGeneticsMolecular BiologyBiochemistryCancer ResearchMolecular Medicine
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy